)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Arecor Therapeutics (AREC) investor relations material
Arecor Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary25 Sep, 2025
Executive summary
Strategic focus on diabetes and cardiometabolic diseases, prioritizing high-value R&D and winding down non-core Tetris Pharma operations.
Lead product AT278, an ultra-concentrated rapid-acting insulin, advancing toward Phase 2 clinical studies in 2H 2026, supported by a co-development partnership with Sequel MedTech.
Oral GLP-1/peptide delivery platform progressing, with key preclinical/PK data expected in 2H 2025.
Strengthened financial position through non-dilutive royalty financing with Ligand Pharmaceuticals, providing up to $11 million, and expanded IP portfolio.
Formation of a new Scientific Advisory Board to support oral drug delivery strategy.
Financial highlights
Revenue stable at £2.0 million for 1H 2025; partner revenue increased to £1.0 million, while product revenue decreased due to Tetris Pharma wind-down.
R&D expenses reduced to £1.3 million (1H 2024: £1.7 million); SG&A costs also down due to Tetris reduction.
Loss after tax narrowed to £2.5 million (1H 2024: £4.6 million).
Cash at 30 June 2025 was £1.9 million, with $7 million/£5.2 million received post-period from Ligand deal.
Gain on disposal of non-Ogluo Tetris Pharma products recognized as an exceptional item.
Outlook and guidance
Cash runway extended into 1H 2027, supporting all phase two enabling costs and ongoing R&D.
Phase 2 clinical study for AT278 targeted for 2H 2026, with enabling activities underway and positive FDA feedback.
Oral GLP-1/peptide platform development ongoing, with key data expected in 2H 2025.
Strategic intent to expand oral peptide delivery platform and pursue new partnerships.
What is the strategic intent for AT278 beyond Phase 2?
What data will inform oral GLP-1 next steps?
What are the terms of the Ligand warrants?
FDA feedback on AT278 Phase 2 design?
Oral peptides: Next steps for bioavailability?
How will the AT278 Phase 2 study be funded?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arecor Therapeutics earnings date
H2 202521 Apr, 2026
Next Arecor Therapeutics earnings date
H2 202521 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Arecor Therapeutics PLC is a biopharmaceutical company specializing in the development of enhanced pharmaceutical formulations. The company applies its proprietary technology to improve the stability, efficacy, and delivery of existing biologics, peptides, and therapeutic proteins. Its pipeline includes proprietary and partnered programs focused on diabetes, critical care, and other therapeutic areas. The company is headquartered in Cambridge, United Kingdom, and its shares are listed on the London Stock Exchange (LSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage